Posted by ABMN Staff on Mar 29th, 2024
Truist Financial began coverage on shares of Merus (NASDAQ:MRUS – Free Report) in a research note published on Thursday morning, MarketBeat reports. The brokerage issued a buy rating and a $69.00 price objective on the biotechnology...
More of this article »